Clinical Trial

DREAM Study: DNA/RNA-NGS Co-Testing in Driver-Negative, Treatment-Resistant NSCLC

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 26, 2025 (before its estimated January 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The study is divided into two parts, Part A and Part B. The purpose of Part A is to reveal the proportion of NSCLC patients who are primarily resistant to first-line non-targeted therapy due to the omission of driver genes (especially fusion variations) by DNA-NGS, the median PFS of patients in the first line, and clinical characteristics through synchronous co-testing of DNA and RNA NGS. The purpose of Part B is to compare the difference in ORR between patients with driver gene positivity identified through synchronous co-testing of DNA and RNA NGS who receive and do not receive targeted therapy.
Trial Details
NCT Number NCT06846762
Lead Sponsor Baohui Han
Conditions Non-Small Cell Lung Cancer
Enrollment 508 participants
Start Date 2025-03-01
Primary Completion 2026-01-01 (estimated)
Study Completion 2027-01-01 (estimated)
Updated on ClinicalTrials.gov 2025-02-26